Scientific due diligence and business development
How he helps founders
Andrew helps founders turn university research into fundable companies. He works with them on licensing negotiations with tech transfer offices, pitch deck and investor narrative development, SBIR/STTR strategy, market assessment, and scientific due diligence. He's equally comfortable digging into the science and the deal terms, always with the goal of bringing new medicines to patients.
Track record
Andrew has advised academic inventors, university tech transfer offices, and early-stage companies across CNS, autoimmune, oncology, and rare disease. He serves as fractional CEO of an autoimmune cell therapy spinout. Before consulting, he was Director of Biology at Convelo Therapeutics, where he purpose-built a state-of-the-art preclinical lab for assessing efficacy of pro-remyelinating compounds.
Background
Andrew holds a PhD in Physiology and Biophysics from Case Western Reserve University and a BA from Oberlin College. He completed postdoctoral training in Clinical Neurosciences at the University of Calgary Cumming School of Medicine. His first-author research on myelin pathology in MS appears in PNAS, Annals of Neurology, and Nature Chemical Biology. He co-chaired the Myelin Gordon Research Seminar and served on the board of the MS Society of Canada's Alberta & NWT Division. He is based in Northeast Ohio.